2012
DOI: 10.1016/j.lungcan.2011.11.018
|View full text |Cite
|
Sign up to set email alerts
|

Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
19
1

Year Published

2013
2013
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 19 publications
(22 citation statements)
references
References 23 publications
2
19
1
Order By: Relevance
“…Despite some reports showing increased values in affected patients, [36][37][38] most studies (and those including a higher number of subjects) reported a decrease of serum EGFR in cancer patients, with a proportional impact on survival. 18,[39][40][41][42][43][44] This supports the hypothesis that serum EGFR could be a different isoform with a physiological and tumorprotective role in the control of the EGFR-regulated signaling. 34 Similarly, we observed a reduction of serum EGFR in OSCC patients, but it was not possible to recognize any important impact on survival.…”
Section: Discussionsupporting
confidence: 78%
See 1 more Smart Citation
“…Despite some reports showing increased values in affected patients, [36][37][38] most studies (and those including a higher number of subjects) reported a decrease of serum EGFR in cancer patients, with a proportional impact on survival. 18,[39][40][41][42][43][44] This supports the hypothesis that serum EGFR could be a different isoform with a physiological and tumorprotective role in the control of the EGFR-regulated signaling. 34 Similarly, we observed a reduction of serum EGFR in OSCC patients, but it was not possible to recognize any important impact on survival.…”
Section: Discussionsupporting
confidence: 78%
“…In the international literature, several studies have evaluated the diagnostic potential of serum EGFR in other tumors (in particular breast, lung, and ovarian tumors) with conflicting results. Despite some reports showing increased values in affected patients, most studies (and those including a higher number of subjects) reported a decrease of serum EGFR in cancer patients, with a proportional impact on survival . This supports the hypothesis that serum EGFR could be a different isoform with a physiological and tumor‐protective role in the control of the EGFR‐regulated signaling .…”
Section: Discussionmentioning
confidence: 69%
“…The kinase domain of isoform1 of ErbB1 did not show any significant similarities with that of the other three isoforms ( Figure 1). Previous studies have demonstrated that only the first isoform is essentially involved in lung cancer (www.uniprot.org/uniprot/P00533) [9]. On the contrary, the kinase domains of all the five isoforms of ErbB2 show significant similarities (Figure 2).…”
Section: Sequence and Structure Analysismentioning
confidence: 90%
“…Although ErbB1 has four isoforms produced by alternative splicing, only the first isoform is primarily involved in lung cancer (www.uniprot. org/uniprot/P00533) [9]. ErbB2 has five isoforms (www.uniprot.org/ uniprot/P04626).…”
Section: Sequence and Structure Analysismentioning
confidence: 99%
“…HER-1 is a glycosylated transmembrane protein belonging to the tyrosine kinases ErbB family of receptors, which are key regulators of several biological processes, is implicated in tumor development and it is highly expressed in many human tumors, and also in 40-80 % of patients with non-small cell lung cancer (NSCLC) (Cohen 2001;Maramotti et al 2012). NSE is a glycolitic enzyme that provides information to cancer course and treatment outcome of small cell lung carcinoma (SCLC) (Fu et al 2012), and CEA is a glycoprotein involved in cell adhesion, and it is the most widely investigated tumor biomarker in various tumors such as colorectal, stomach, pancreas, liver, ovarian, breast, prostate, thyroid, bladder, kidney, and lung (Qu et al 2013;Grunnet and Sorensen 2012).…”
Section: Introductionmentioning
confidence: 99%